Dynavax Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors Business Wire DALLAS -- June 21, 2013 Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce that a federal class action lawsuit has been filed against Dynavax Technologies Corporation (“Dynavax” or “Company”) (Nasdaq: DVAX). The firms are investigating additional legal claims against the officers and directors of Dynavax during the period of April 26, 2012 and June 10, 2013 (the “Class Period”). If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, or via email at WBriscoe@TheBriscoeLawFirm.com, or Zachary Groover at Powers Taylor, LLP, toll free (877) 728-9607, via email at firstname.lastname@example.org. There is no cost or fee to you. In a recently filed federal class action complaint, Dynavax and certain of its officers and directors were charged with violating certain provisions of the Securities Exchange Act of 1934. Specifically, the complaint alleges that among other things, defendants’ misrepresented and/or failed to disclose that: (a) the clinical trial for HEPLISAV was flawed since the trial demographics did not represent the population of the United States; (b) the trial did not have a one-year safety follow-up, which is typically required for vaccines; (c) the trial lacked information concerning concomitant use with other vaccines; (d) given the novel adjuvant that the HEPLISAV vaccine contains, the clinical trial for HEPLISAV was flawed because the safety database size was inadequate to rule out rare adverse autoimmune events; (e) Dynavax failed to provide the FDA with sufficient data concerning its manufacturing processes and controls for HEPLISAV on its BLA; and (f) as a result of the above, the Company’s positive statements about the Company’s outlook, including the statements about its launch of HEPLISAV in 2013, were materially false or misleading. According to the complaint, when the true facts were revealed, the Company’s shares dropped 73% from their Class Period high. Shareholder rights attorney Willie Briscoe said, “Recent revelations about alleged improper business practices and procedures regarding key aspects of Dynavax’s business and other misleading financial statements have prompted the firms to investigate possible breaches of fiduciary duties and other violations of state law by Dynavax’s officers and directors. Based on our investigation, we are prepared to pursue litigation to preserve the company and the value of Dynavax stock for all shareholders.” The Briscoe Law Firm, PLLC is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters. Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions. Contact: The Briscoe Law Firm, PLLC Willie Briscoe, 214-239-4568 WBriscoe@TheBriscoeLawFirm.com or Powers Taylor, LLP Zachary Groover, 877-728-9607 email@example.com
Dynavax Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and
Press spacebar to pause and continue. Press esc to stop.